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Background: Individuals with deficiencies of pulmonary surfactant protein C (SP-C) develop interstitial lung disease
(ILD) that is exacerbated by viral infections including respiratory syncytial virus (RSV). SP-C gene targeted mice
(Sftpc -/-) lack SP-C, develop an ILD-like disease and are susceptible to infection with RSV.
Methods: In order to determine requirements for correction of RSV induced injury we have generated compound
transgenic mice where SP-C expression can be induced on the Sftpc -/- background (SP-C/Sftpc -/-) by the
administration of doxycycline (dox). The pattern of induced SP-C expression was determined by
immunohistochemistry and processing by Western blot analysis. Tissue and cellular inflammation was measured
following RSV infection and the RSV-induced cytokine response of isolated Sftpc +/+ and -/- type II cells
determined.
Results: After 5 days of dox administration transgene SP-C mRNA expression was detected by RT-PCR in the lungs
of two independent lines of bitransgenic SP-C/Sftpc -/- mice (lines 55.3 and 54.2). ProSP-C was expressed in the
lung, and mature SP-C was detected by Western blot analysis of the lavage fluid from both lines of SP-C/Sftpc -/-
mice. Induced SP-C expression was localized to alveolar type II cells by immunostaining with an antibody to proSP-
C. Line 55.3 SP-C/Sftpc -/- mice were maintained on or off dox for 7 days and infected with 2.6x107 RSV pfu. On day
3 post RSV infection total inflammatory cell counts were reduced in the lavage of dox treated 55.3 SP-C/Sftpc -/-
mice (p = 0.004). The percentage of neutrophils was reduced (p = 0.05). The viral titers of lung homogenates from
dox treated 55.3 SP-C/Sftpc -/- mice were decreased relative to 55.3 SP-C/Sftpc -/- mice without dox (p = 0.01). The
cytokine response of Sftpc -/- type II cells to RSV was increased over that of Sftpc +/+ cells.
Conclusions: Transgenic restoration of SP-C reduced inflammation and improved viral clearance in the lungs of SP-
C deficient mice. The loss of SP-C in alveolar type II cells compromises their response to infection. These findings
show that the restoration of SP-C in Sftpc -/- mice in response to RSV infection is a useful model to determine
parameters for therapeutic intervention.
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SP-C is an abundant surfactant associated lipoprotein
expressed in alveolar type II epithelial cells that
synthesize and secrete pulmonary surfactant into the air-
space. While SP-C confers dramatic surface activity it is
not essential for perinatal transition to breathing. Indivi-
duals lacking SP-C survive but develop a variety of inter-
stitial or fibrotic lung disease outcomes [1]. SP-C related
disease can occur as acute postnatal respiratory distress
or with slow onset that is identified as respiratory insuf-
ficiency during childhood through adulthood [2,3]. The
molecular pathogenesis of SP-C related lung disease
includes loss of gene expression without defined muta-
tions, decreased expression from non-coding promoter
mutations, and most commonly mutations in the SP-C
coding gene (SFTPC) [4-6]. The SFTPC mutations have
distinct consequences, altering mRNA splicing, propro-
tein structure, protein expression, or processing. These
mutation-derived defects induce both a cellular stress in-
jury due to altered structure and processing of the SP-C
proprotein and a decrease in the amount of functional
mature SP-C lipoprotein released into the airspace. SP-C
deficient mice (Sftpc -/-) were generated in order to de-
termine the role of SP-C in pulmonary homeostasis and
distinguish injury based upon deficiency versus injury
induced by aberrant SP-C expression products. On the
129S6 background Sftpc -/- mice develop parenchymal
lung injury with age that is similar to the interstitial lung
disease (ILD) reported for individuals with deficiencies
of SP-C or SFTPC mutations [7,8].
Respiratory crises in affected SFTPC individuals have
been linked to viral infections that include influenza,
parainfluenza, and RSV [1,9,10]. RSV is a common
pediatric respiratory pathogen that elicits an intense
inflammatory injury primarily in infants but can also
re-infect and complicate adult chronic obstructive pul-
monary disease (COPD). RSV infection induces airway
inflammation, wheezing, and in some cases inflamma-
tion involving the lower airspaces [11,12]. There is a
growing appreciation of the role of the alveolar epithe-
lium in the production of inflammatory mediators and
the regulation of innate defense [13]. The infection
related exacerbations of affected individuals indicate that
SP-C confers protection and may limit infection from
progressing to the alveolar compartment.
Sftpc -/- mice are susceptible to RSV infection with
decreased viral clearance and a more robust and sus-
tained pulmonary inflammation [14]. The host pulmon-
ary immune response to RSV is complex and for both
humans and mice includes pathogen receptor Toll-like
receptor-3 (TLR3) activation of inflammatory gene ex-
pression and recruitment of the innate cellular defenses
[14]. Sftpc -/- mice had increased lung inflammation
when challenged with a synthetic ligand for TLR3, andSP-C phospholipid preparations blocked TLR3 mediated
signaling in vitro. The increased severity of RSV infec-
tion in the Sftpc -/- mice and the impact of viral infec-
tion in SFTPC related patients indicate that SP-C is a
significant component of the pulmonary innate immune
system.
We hypothesized that genetic restoration of SP-C
would reduce RSV injury in the lungs of SP-C deficient
mice. To test that hypothesis transgenic mice were gen-
erated that conditionally express and process proSP-C in
the lungs of SP-C deficient mice. The data show that
SP-C expression for seven days was sufficient to provide
protection from RSV induced injury. Development of
this in vivo model to genetically regulate SP-C expres-
sion will aid in designing therapeutic intervention and
identifying RSV-induced genes regulated by SP-C.
Methods
Inducible SP-C transgene construction and genetic
crosses to establish a regulated SP-C model
CCSP-rtTA transgenic mice that express the tetracycline
transactivator protein were previously generated and
characterized. The CCSP-rtTA transgenic line expresses
the tetracycline transactivator within twenty-four hours
of administration of the tetracycline analog-doxycycline
(dox) primarily in the alveolar epithelium rather than
bronchiolar epithelial expression seen for the endogen-
ous CCSP gene [15,16]. An available SP-C-rtTA trans-
genic line expressed low levels of the rtTA mRNA
without dox induction and thus due to the background
leak, was less useful for the studies in this manuscript
[17]. Because the CCSP-rtTA transgenic line was tightly
regulated by dox administration and the transgene was
also expressed in the SP-C producing type II cells the
CCSP-rtTA transactivator line was used to breed and es-
tablish the model of inducible SP-C replacement. A sec-
ond transgene was constructed that would conditionally
express SP-C in response to the CCSP-rtTA activator.
The full-length murine SP-C cDNA was cloned direc-
tionally into unique EcoR1 (5’) and XbaI (3’) restriction
sites downstream of the tetO7 CMV promoter in the
plasmid pUHD15-1 [15,18]. Transcriptional activation to
express the linked SP-C cDNA requires binding of the
rtTA protein in the presence of dox to the seven binding
sites (tetO7) adjacent to the CMV promoter. XhoI-
HindIII double digestion was used to release the
tetO7CMV-SP-C transgene from the bacterial plasmid
backbone for purification and microinjection. Potential
transgene founder animals were screened by PCR ana-
lysis of tail clip DNA. Transgene positive tetO7CMV-SP-
C founder animals were bred to Sftpc -/- mice that were
then crossed to the CCSP-rtTA/Sftpc -/- mice in order
to generate compound genetically modified mice carry-
ing both transgenes and the targeted Sftpc -/- locus.
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to test for doxycycline (dox) induction of transgene
mediated SP-C expression. Animal studies were per-
formed under protocols approved by the Children’s Hos-
pital Research Foundation Institutional Animal Care and
Use Committee (Cincinnati, Ohio).
Detection of inducible transgene mRNA and protein
expression
The CCSP-rtTA/tetO7-SP-C/Sftpc -/- mice were placed
on commercial dox supplemented chow for five days
prior to analysis. SP-C mRNA expression was assessed
by RTPCR of cDNA prepared from total lung RNA iso-
lated from Sftpc +/+, Sftpc -/-, single transgene Sftpc -/-
and compound CCSP-rtTA/tetO7-SP-C/Sftpc -/- mice
fed either normal or dox chow. Expression and proces-
sing of the proSP-C protein to the mature SP-C was
assessed by Western blot. An antibody to the 21kD
proSP-C (Seven Hills Bioreagents, WRAB-9337) was
used to identify expression of the full-length proSP-C in
lung tissue and a second antibody (Seven Hills Biorea-
gents, WRAB-76694) to detect the 4.5kD processed ma-
ture SP-C in both tissue and bronchoalveolar lavage
fluid (BALF).
Immunohistochemistry and localization of induced SP-C
protein in the lungs
The lungs of line 55.3 CCSP-rtTA/tetO7-SP-C/Sftpc -/-
and Sftpc +/+ mice on or off of dox were inflation fixed,
paraffin embedded and five micron sections processed
for immunohistochemistry with the anti proSP-C anti-
body. The primary antibody - WRAB-9337 was used at
1:1,000 dilution overnight at four degrees and the sec-
ondary HRP conjugated goat anti-rabbit antibody used
at 1:200 dilution for thirty minutes and immunoreactiv-
ity visualized by reaction with nickel enhanced diamino-
benzidine (Sigma-Aldrich Co.) and nuclear fast red
counter stain. Lung histopathology after infection was
visualized using conventional hematoxylin and eosin
staining. Airway goblet cell transformation was deter-
mined by alcian blue histochemical staining (Poly Scien-
tific R&D Corp.).
RSV infection, viral titer, and inflammation of CCSPrtTA/
tetO7-SP-C/Sftpc -/- mice
Seven-week old mice were placed on dox chow for seven
days, anesthetized by isoflurane inhalation and then
infected by oral aspiration with 2.6 × 107 pfu or RSV cell
growth media as non-viral control [14]. Three days after
RSV infection viral titers were quantified by serial dilu-
tion of lung homogenates in triplicate on Hep2 cells.
Plaques were visualized by immuno-staining of fixed
cells with a monoclonal antibody to RSV F protein(Fitzgerald Industries Int. Inc., 10R-R113B) and counter-
stained with nuclear fast red (n = 5 mice per group) [14].
Bronchoalveolar lavage fluid (BALF) was obtained with
three sequential lavages using one ml aliquots of phos-
phate buffered saline (3 instillation cycles with each
aliquot). Total cell counts were determined by visual
counting using a hemocytometer and differential cell
counts determined from cytospin preparations visualized
with DiffQuik staining (Diff Quick Stain Set, Siemens).
Preparation of SP-C-phospholipid liposomes and
inhibition of RSV infection
Native SP-C was purified by C8 liquid chromatography
of bovine lung lavage, as previously described [14].
Briefly, dipalmitoylated SP-C was identified as a single
peak at m/z 4058.4 Da by matrix assisted laser desorp-
tion ionization time of flight (MALDI-TOF) mass spec-
trometry. The purified SP-C stock solution was free of
detectable levels of endotoxin. An SP-C stock solution
in 7:1:1 methanol/chloroform/water (v/v/v) was added
to 10 mg/ml stock solutions of phospholipid liposomes
prepared with representative surfactant phospholipids,
dipalmitoyl-phosphatidylcholine (DPPC) and palmitoyloleoyl-
phosphatidylcholine (POPC) (Avanti Polar Lipids) at a
DPPC:POPC molar ratio of 7:3 with isolated SP-C incor-
porated 5% by weight. DPPC/POPC liposomes (7:3 mol/
mol) without SP-C were used as control liposomes. Lipo-
some preparations were dried under nitrogen at 45C.
Endotoxin free Dulbecco’s phosphate buffered saline was
added to the dried film at 45C, vortexed for 10s and soni-
cated for 10s to yield vesicle preparations at a final con-
centration of 25 mg/ml phospholipid. The effect of SP-C
on inhibition of viral infection in vitro was determined.
60,000 Hep2 cells were seeded per well of 12 well dish.
The next day synthetic phospholipid liposomes with or
without SP-C (25ug/ml) were overlaid onto cell mono-
layers and incubated for one hour prior to RSV infection
at a multiplicity of infection (MOI) of 2, held at 37, 5%
CO2 for two days and the monolayers fixed, stained with
the anti-RSV F protein antibody, counterstained and pla-
ques counted. Experiments were performed in triplicate.
Determination of cytokine expression by isolated type II
cells of Sftpc +/+ and -/- mice following infection
Type II cells were isolated using minor modifications of
a published procedure [19,20]. Following humane eu-
thanasia, the instillation of Dispase (Gibco) into the
lungs of five-week old mice was used to initiate alveolar
enzymatic digestion of epithelial cells followed by instil-
lation of low melt agarose to block release and contam-
ination from airway respiratory epithelial cells. Digested
cell suspensions were filtered, overlaid onto to CD45,
CD32 antibody coated plates to capture non-epithelial
cells. The non-adherent type II cells were recovered by
Figure 1 Identification of transgenic mice that express SP-C in
response to doxycycline administration. Panel A: PCR results
identify founder transgenic Sftpc -/- mice carrying either the dox
responsive SP-C cDNA (tetO7-SP-C), the CCSP promoter directing
expression of the tetracycline transactivator (CCSP-rtTA), or a mouse
positive for both transgenes and the disrupted Sftpc locus
(neomycin positive, SP-C negative) indicated by the arrow. Panel B:
Lung cDNA from transgenic CCSP-rtTA/tetO7-SP-C -Sftpc -/- mice
was assayed for dox induced expression of SP-C. Two CCSP-rtTA
/tetO7-SP-C -Sftpc -/- founder lines, 55.3 and 54.2 expressed SP-C
when fed dox chow (+ lanes). No SP-C expression was detected in
the absence of dox (-lanes), or in the lungs of single transgenic
tetO7-SP-C-Sftpc -/- mice on or off dox (last two lanes). Arrow
indicates SP-C cDNA band.
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(Lonza). The type II cells were seeded (150,000 cells per
well) onto forty-eight well dishes coated with a 70:30
vol/vol mixture of Cultrex (Trevigen Inc.): rat-tail colla-
gen (BD Bioscience) basement membrane matrix. Cells
were maintained for three days to allow recovery of the
differentiated type II cell phenotype [19]. Triplicate wells
for both Sftpc +/+ and -/- cells were subject to infection
at a MOI of 2. The media was removed at 24 hours post
infection. Cell debris was removed by centrifugation and
cytokine concentrations in the supernatant determined
by ELISA assay (R&D systems).
Statistical analysis
Potential statistical significance was determined using
one-way ANOVA or Student’s t test.
P values at or below 0.05 were accepted as significant.
Results
Generation of inducible SP-C replacement model:
identification of founder double transgene and Sftpc-/-
compound mice
The CCSP-rtTA transgenic line that expresses the tetra-
cycline transactivator protein in distal airway and alveo-
lar epithelial cells was previously generated and shown
to primarily direct alveolar specific expression of rtTA
rather than the bronchiolar-Clara cell expression for the
endogenous CCSP gene [15,16]. Thus the CCSP-rtTA
transgenic mice would potentially activate expression of
the SP-C responder transgene (tetO7CMV-SP-C) in the
desired surfactant producing type II cells.
Seven tetO7CMV-SP-C transgene founder mice were
identified. Four of the founder tetO7CMV-SP-C mice
were successfully bred to Sftpc -/- mice on the 129S6
background and then crossed with CCSP-rtTA/Sftpc -/-
mice in order to test F1 offspring for inducible transgene
SP-C expression to selectively replace SP-C in the lungs
of the SP-C deficient, Sftpc -/- mice.
SP-C negative and neomycin positive result identifies
the disrupted Sftpc locus (Figure 1A, lane 3). As depicted
in Figure 1A, single transgene tetO7CMV-SP-C mice on
Sftpc -/- background were identified in lane 4 and single
transgene CCSP-rtTA mice on Sftpc -/- background, lane
5. Arrow indicates desired genotype of double transgene
positive and Sftpc -/- compound mice.
mRNA expression
The CCSP-rtTA transactivator line used in this study is
tightly regulated by dox administration, with expression
of target tetO7-reporter transgene achieved within
18 hours of administration [17]. The F1 offspring of each
line of CCSP-rtTA/tetO7-SP-C/Sftpc -/- mice were pro-
vided commercial dox supplemented chow for five days
and inducible SP-C expression tested by RTPCR analysisof total lung cDNA. Two founder CCSP-rtTA/tetO7-SP-
C lines, 54.2 and 55.3 expressed SP-C mRNA (lane 1 vs
lane 3, Figure 1B). No SP-C mRNA was detected in the
lungs of either the line 55.3/Sftpc -/- or 54.2/Sftpc -/-
mice without dox (lanes 2 and 4, Figure 1B) or in single
transgene tetO7CMV-SP-C/Sftpc -/- mice maintained on
dox (lanes 5 and 6, Figure 1B). Thus re-expression of
SP-C is tightly controlled, requiring the presence of both
transgenes and dox administration.
Both the 55.3/Sftpc -/- and 54.2/Sftpc -/- lines were bred
onto the 129S6/Sftpc -/- background for 9 generations
to generate genetically uniform lines of CCSP-rtTA
/tetO7-SP-C/Sftpc -/- mice. The backcrosses established
the inducible transgenes on the susceptible 129S6
strain of Sftpc -/- mice that develop ILD like disease
with age [8].
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SP-C is expressed as a 21kD proprotein that is proteo-
lytically processed to a 4.5kD peptide that is incorpo-
rated into lamellar bodies for secretion. Using an
antibody specific to proSP-C the 21kD proSP-C protein
was detected by Western blot analysis of lung homoge-
nates from the line 55.3 and line 54.2 SP-C/Sftpc -/-
mice. Expression of proSP-C in line 55.3/Sftpc -/- mice
is shown in the top panel of Figure 2A. Western blot
analysis with an antibody specific to the mature 4.5kD
form of SP-C detected significant SP-C in the BALF and
a small amount of mature SP-C in lung tissue of the line
55.3/Sftpc -/- mice (lower panel, Figure 2A). These
results indicate that the proSP-C is correctly expressed,
processed to the mature protein in the lungs and
secreted into the airspace. No proSP-C or mature SP-C
protein was detected in the lungs of non-induced lineFigure 2 Lung expression, processing, and localization of inducible S
processed SP-C expression in 55.3/Sftpc -/- mice. An antibody to proSP-C d
maintained on dox (white arrows). Lower row; Antibody to the proteolytica
indicating secretion into the airspace (dark arrows). SP-C protein was only d
fluid from Sftpc +/+ mice are shown as positive controls and Sftpc -/- mice
Immuno-localization of dox-induced proSP-C in the lungs of line 55.3/Sftpc
Lung tissue from Sftpc +/+ mice ,Immunostaining with anti proSP-C antibo
staining was detected in the lungs of line 55.3/Sftpc -/- mice without dox i
lungs of dox treated line 55.3/Sftpc -/- mice, similar to Sftpc +/+ mice in pa
dox treatment.55.3/Sftpc -/- mice (no dox lanes). Antibody specificity
was verified using lung tissue from Sftpc +/+ mice as a
positive control for detection of proSP-C in lung tissue
and secreted mature SP-C in lavage fluid (right panel,
Figure 2A). Sftpc -/- mice served as a negative control
(right panel). Because induced SP-C expression appeared
more robust in the line 55.3 /Sftpc -/- mice, this line was
expanded and used in the following studies.
In situ expression of the inducible SP-C transgene
Immunohistochemical staining was used in order to de-
termine the level and pattern of SP-C expression
induced in the lungs of line 55.3/Sftpc -/- mice after
seven days of dox activation. Staining with an anti
proSP-C antibody identified alveolar cell specific expres-
sion of SP-C (Figure 2B). The pattern of proSP-C stain-
ing for dox treated 55.3/Sftpc -/- mice (Figure 2B, panelP-C expression. Part A: Top row; Western blot analysis of proSP-C and
etected proSP-C in the lung homogenates from line 55.3/Sftpc -/- mice
lly processed SP-C detected the mature 4.5kD SP-C in BAL fluid
etected in the dox-treated 55.3/Sftpc -/- animals. Lung tissue and BAL
as negative controls for the specificity of SP-C immunostaining. Part B:
-/- mice: Panel A, Sftpc +/+ lung with no primary antibody. Panel B,
dy. Staining localized to alveolar type II cells. Panel C, No proSP-C
nduction. Panel D, proSP-C was detected in a type II cell pattern in
nel B. No alteration of lung morphology was observed by
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tive type II cells seen in wild type - Sftpc +/+ mice
(Figure 2B, panel B). No SP-C immunostaining was
detected in the lungs of 55.3/Sftpc -/- mice without dox
induction (Figure 2B, panel C). Sections treated without
primary antibody, Figure 2B, panel A) were devoid of
staining. In the current study induced SP-C was detected
only in the lungs of the double transgenic line 55.3/Sftpc -/-
mice administered dox indicating tight regulation of the
proSP-C transgene. Dox treatment did not appear to
alter lung morphology relative to Sftpc +/+ mice (com-
pare Figure 2B, panels C and D vs panel B).
Effect of SP-C reconstitution on RSV mediated lung injury
Line 55.3/Sftpc -/- mice were maintained on continuous
dox administration for seven days prior to RSV infec-
tion. Three days after infection the lungs were subject to
bronchoalveolar lavage, or fixed for histology, or
removed and homogenized for viral titer determination
by in vitro RSV focus forming plaque assay. CellularFigure 3 Re-expression of SP-C reduces cellular inflammation and vira
infection, inflammatory cells in recovered BALF were analyzed for total cell
(panel B). Viral titers in infected lungs were determined by plaque assay of
from the BALF of media treated control mice were similar to Sftpc +/+ mic
neutrophils were increased in the BALF from RSV infected line 55.3/Sftpc -/
viral titer were all reduced in lungs of line 55.3/Sftpc -/- mice maintained oinflammation was reduced in the lungs of RSV infected
line 55.3/Sftpc -/- mice maintained with dox. Total cell
counts in the BALF of the dox treated line 55.3/Sftpc -/-
mice were decreased by 58% and the percentage of neu-
trophils in recovered BALF was also decreased relative
to non-dox treated line 55.3/Sftpc -/- mice (Figure 3).
Viral loads were decreased by 40% in the lungs of dox
activated line 55.3/Sftpc -/- mice relative to compound
transgenic mice without dox activation (Figure 3, lower
panel). Administration of dox to activate reporter gene
expression was shown to not alter RSV infectivity [21].
Dox administration to line 55.3/Sftpc -/- and Sftpc +/+
media control mice did not increase BALF inflammatory
cell counts (Figure 3 top panel).
Mild perivascular, peribronchiolar infiltrates were
observed in the lungs of infected Sftpc +/+ mice. In con-
trast, diffuse alveolar inflammatory infiltrates and inter-
stitial inflammation was observed in the lungs of the
line 55.3/Sftpc -/- mice without dox. The apparent in-
flammatory injury was decreased in the lungs of linel load in lungs of infected line 55.3/Sftpc -/- mice. Following RSV
s (panel A) and the numbers of neutrophils determined from cytospins
lung homogenates on day 3 post infection (panel C). Total cell counts
e on dox (lanes 1-3 panel A). Total cell counts and the percent
- mice compared to Sftpc +/+ mice on dox. Total cells, neutrophils and
n dox versus animals without dox (no SP-C) (5 mice per group).
Figure 5 SP-C inhibits viral infection in vitro. Hep2 cells were
infected with RSV alone, or with RSV following a one hour pre-
treatment with phospholipid liposomes +/- SP-C. The synthetic
phospholipid liposomes did not reduce viral plaque numbers while
the liposome with incorporated SP-C reduced the viral plaque
counts. N = 3.
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infection (Figure 4). The observed pathology in non-dox
line 55.3/Sftpc -/- mice was similar to the increased in-
jury originally reported for RSV infection of Sftpc -/- mice
[14]. The reduction in observable tissue inflammation is
consistent with the reduced viral titer and inflammatory
cell counts with dox-induced restoration of SP-C.
Isolated SP-C reduces infectivity in vitro
In order to determine if SP-C directly inhibits initial
viral infection, the RSV permissive cell line Hep2 was
pretreated with phospholipid liposomes or phospholipid
liposomes with exogenous SP-C for one hour prior to
viral infection (Figure 5). Exposure of the Hep2 cells to
liposomes without SP-C did not alter the viral titer com-
pared to RSV infection alone. However, liposomes with
SP-C reduced the viral titer by 73%. The SP-C
dependent reduction indicates that SP-C associated with
surfactant phospholipids inhibits viral-epithelial cell
interactions that are essential for infection.
The type II cells from SP-C deficient mice have an
increased inflammatory response to RSV
Isolated Sftpc -/- type II cells in culture had elevated in-
trinsic expression of cytokines IL-6, TNFα, KC and to a
lesser extent IL1-β than type II cells from the lungs of
Sftpc +/+ mice (Figure 6). Upon challenge with the viral
dsRNA surrogate poly (I:C) or RSV infection (Figure 6A
and B respectively) the cytokine response by Sftpc -/-
type II cells was increased relative to Sftpc +/+ cells.Figure 4 Restoration of SP-C reduces RSV induced lung histopatholog
infiltration in the lungs of Sftpc +/+ mice (panel A). Lungs of the line 55.3/S
diffuse cellular infiltration throughout the airspaces (panel B) similar to the
55.3/Sftpc -/- mice with dox-induced re-expression of SP-C prior to RSV infe
sections are representative of sections from five mice.These results indicate that the loss of SP-C renders the
alveolar type II cell more susceptible to infection driven
inflammation that occurs in part by TLR3 dependent ac-
tivity (poly I:C ligand for TLR3).
Discussion
SP-C deficient mice have increased inflammation and
prolonged recovery from injury following infection withy. RSV induced mild perivascular, bronchiolar inflammatory cell
ftpc -/- mice (no SP-C) without dox had interstitial inflammation and a
previously reported histopathology in Sftpc -/- mice [14]. The lungs of
ction had reduced observable histopathology (panel C). Presented
Figure 6 SP-C deficiency increases the type II cell cytokine response to RSV infection and TLR3 challenge. Cytokine levels were measured
in the culture media of Sftpc +/+ and -/- type II cells challenged with the TLR3 ligand poly I:C (Panel A) or by RSV infection (Panel B). Basal levels
of cytokine expression were elevated in the media from Sftpc -/- type II cells and the response to poly I:C or virus was increased relative to the
Sftpc +/+ cells. Cytokine concentrations are in pg/ml (x axis). N = 3.
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was generated wherein proSP-C was expressed, processed
to mature SP-C, and secreted in the airspace. When SP-C
expression was induced in the lungs of Sftpc -/- mice prior
to RSV infection, the pulmonary infiltration, viral titers,and morphologic indicators of injury were reduced. The
increased susceptibility of Sftpc -/- mice to RSV and partial
rescue by short-term alveolar expression supports the con-
cept that SP-C contributes to innate alveolar defense
against viral infection.
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defense by multiple mechanisms
Pulmonary surfactant is essential for normal respiration
and for protection from inspired microorganisms. Rare
forms of familial ILD have been linked to decreased SP-
C expression and indicate that SP-C is required for lung
homeostasis. The age of onset and severity of disease
can vary significantly between affected family members
ranging from an immediate neonatal RDS to childhood
or adult onset ILD/IPF [2]. This variable progression
suggests the activity of additional disease modifiers.
The complex underlying molecular pathology of SP-C
related ILD results from decreased SFTPC gene expres-
sion through mutations that alter the structure and
abundance of either mRNA or protein. In addition, fa-
milial SP-C deficient ILD has been reported without any
structural SFTPC mutation [4,5]. The affected indivi-
duals appear to be a true null phenotype. A recent re-
port identifies individuals with SP-C deficiency due to
clustered mutations in a distal upstream promoter re-
gion and implicates this region as an essential regulatory
element for SFTPC gene expression [6]. Thus, the sim-
ple absence of SP-C can produce neonatal and/or child-
hood ILD.
The majority of individuals with SP-C related disease
have mutations in the SFTPC gene. Mutations are
primarily dispersed throughout the region downstream
of the mature peptide altering mRNA splicing, propro-
tein processing, and proprotein structure and folding
[3,22,23]. Mutations that alter processing or structure
can induce both a cellular stress response as well as
produce a net decrease in the amount of the secretory
form of the protein. These distinct genetic alterations
and resulting protein abnormalities may account for
the reported pleiotropic phenotype. The Sftpc -/- mice
have been used to explore the impact of the deficiency
separate from deleterious effects of aberrant forms of
proSP-C.
SP-C abnormalities increase the severity of RSV lung
disease
Viral infections are a risk factor for preexisting condi-
tions that include immunosuppression, cystic fibrosis, or
prematurity [11]. In a similar pattern, the pulmonary
disease in young SFTPC patients can be complicated by
influenza A/B virus or RSV infection. RSV infection is a
common cause of respiratory infections in children that
can vary from mild upper airway disease to severe bron-
chiolitis that requires hospitalization. RSV bronchiolitis
during infancy also increases the incidence of chronic
respiratory conditions such as wheezing, asthma, and al-
lergy later into childhood [11,24]. RSV related exacerba-
tion has occurred in affected individuals either with or
without a defined SFTPC mutation [2,9,10]. In a separatestudy, expression of an SFTPC mutation in vitro ren-
dered the cells more susceptible to RSV infection [25].
In support of the human clinical findings, a sub-strain of
cattle with hereditary SP-C deficiency has an increased
incidence of newborn respiratory distress. These cattle
had increased fatal lung disease following an attempt to
vaccinate against bovine RSV [26]. The findings from
human case histories, as well as bovine and mouse
model of SP-C deficiency indicate that SP-C is an im-
portant factor in both the control of RSV infection and
recovery from RSV infection.
In the current study Sftpc -/- type II cells had
increased basal levels of key cytokines and expressed
increased cytokine levels when challenged with either
synthetic dsRNA or upon RSV infection in vitro. Thus
the absence of SP-C is sufficient to predispose the type
II cell to aberrant inflammation upon viral infection.
These findings indicate that type II cell function can
contribute to alveolar defense during severe RSV infec-
tion that in part relies upon the immune-protective ac-
tivity of SP-C.Restoration of SP-C in type II cells improves the outcome
of RSV infection
RSV infection of Sftpc +/+ and -/- mice produced
increased tissue and cellular inflammation in the lungs
of the Sftpc -/- mice [14]. Recovery from RSV related
disease was incomplete in the lungs of Sftpc -/- mice
thirty days after initial infection. As a first step to deter-
mine how SP-C confers alveolar protection, we have
transiently replaced SP-C in a cell correct manner
in vivo to assess reduction of inflammation and viral
clearance. The SP-C proprotein was expressed and pro-
cessed to the mature peptide that was secreted and
detected in the BALF. SP-C expression was only
detected following dox administration consistent with
tight regulation of the SP-C transgene. Tissue inflamma-
tion and inflammatory cell infiltration was decreased on
day 3 post-infection in the line 55.3/Sftpc -/- mice on
doxycycline while more severe histopathology was ap-
parent in the same mice without the induced SP-C ex-
pression. The incomplete reversal of RSV-induced injury
may reflect the pattern of induced transgenic SP-C ex-
pression in a subset of type II cells when compared to
wild type mice. The presence of the CCSP-rtTA trans-
gene has been reported to alter alveolar size in mice on
a different genetic background than the mice in this
study and by inbreeding of lines of mice [27]. Based
upon histological examination of three sections from
three representative mice in each group there were no
indications of differences in morphology between either
the CCSP-rtTA or tetO7-SP-C transgenic mice or in two
independent lines of the double transgenic-Sftpc -/- mice
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Other surfactant components modify the outcome of RSV
infection
Additional protein and lipid components of pulmonary
surfactant have been reported to influence the pulmon-
ary response to RSV infection. Previous studies have
shown that SP-A and SP-D also reduce injury from RSV
infection. Both SP-A and SP-D (Sftpa-/-, Sftpd -/-) defi-
cient mice were more susceptible to RSV infection. Co-
administration of isolated SP-A with virus at the time of
instillation reduced the cellular inflammation and
increased viral clearance from the lungs of Sftpa -/- mice
[28,29]. However neither SP-A nor D levels were altered
in the BALF from lungs of RSV infected Sftpc -/- mice
relative to Sftpc +/+ mice [14]. Thus neither SP-A nor
SP-D influenced RSV infection in the SP-C deficient
lung.
In the present study, vesicles generated with the major
representative surfactant phospholipid species (DPPC
and POPC) did not reduce the viral infection in vitro.
The DPPC:POPC vesicles complexed with SP-C decreased
RSV infectivity indicating that SP-C associated with major
surfactant phospholipids confers a protective role during
RSV infection. The phospatidylglycerol (PG) derivative
palmitoyloleoyl-phosphatidylglycerol (POPG) is found in
pulmonary surfactant and was shown to independently
suppress RSV infectivity [30]. The activity of pure POPG
was noted at concentrations eight fold above phospholipid
levels tested in this study. It is unknown if POPG in
surfactant-like phospholipid mixtures would confer anti-
viral activity on the order of our SP-C dependent findings.
While not directly comparable, the POPG activity could
exert a synergistic affect with SP-C to modify the outcome
of RSV infection. The surfactant phospholipid composition
of Sftpc -/- mice was unchanged from that of Sftpc +/+
mice inferring that there is no change in potential PG
derived phospholipid antiviral activity between the two
Sftpc genotypes [8].
Immuno-protection by SP-C extends to other lung
pathogens
The function of SP-C as a key protective component of
surfactant was identified in a model of influenza A infec-
tion. The commercial surfactant extract SurfactenW
acted as an adjuvant increasing the effective nasal muco-
sal immunity upon viral challenge [31]. Surfacten lacks
SP-A and SP-D and is enriched in SP-C. Representative
surfactant phospholipid and protein mixtures were
assessed to identify active components that confer the
viral immune response. Synthetic phospholipid mixtures
similar to the commercial Surfacten preparation alone
or in combination with SP-B did not induce a protectiveantiviral response. However addition of SP-C to the
phospholipid preparations produced a nasal IgA re-
sponse equivalent to the Surfacten-influenza mixture
[32]. These findings on SP-C mediated influenza protec-
tion along with the current SP-C regulation of RSV in-
jury directly infer an immune-protective role for SP-C
independent of representative surfactant phospholipids
alone.
Some SFTPC patient histories document recurrent
infections. These findings are supported by a bacterial
infection study in the Sftpc -/- mice demonstrating
reduced clearance of the respiratory pathogen Pseudo-
monas aeruginosa [33]. Taken together these reports
identify a protective role for SP-C during both bacterial
and viral infections.
The Toll-like receptor TLR3 influences the type II cell
response in SP-C deficient mice
While the epithelial response to RSV is complex, cyto-
kine activation and the activity of the Toll-like innate
immune receptors have been shown to be integral to the
inflammatory and epithelial protective reaction to RSV
[34,35]. Because SP-C is synthesized and secreted in the
alveolus we hypothesized that the increased susceptibil-
ity to infection resulted from compromised type II cells.
Sftpc -/- type II cells had increased basal levels of key
cytokines and expressed increased cytokine levels when
challenged in vitro with either the TLR3 specific ligand
poly I:C, or RSV infection. TLR3 has previously been
shown to mediate immune response to RSV infection
and SP-C blocked TLR3 signaling in vitro [14,36]. In
addition Sftpc -/- mice had increased lung inflammation
when challenged in vivo with poly I:C. Our findings indi-
cate that the absence of SP-C is sufficient to predispose
the type II cell to viral infection and stimulate TLR3
mediated inflammatory responses. TLR3 is associated
with intracellular signaling vesicles and SP-C is an obli-
gate membrane or phospholipid associated lipopeptide.
The increased intrinsic expression of inflammatory cyto-
kines by SP-C deficient type II cells suggest the interpret-
ation that under normal conditions there is intracellular
vesicle-to-vesicle interaction where SP-C restrains unwar-
ranted or non-specific activation of TLR3 inflammatory
signaling. Collectively our results support the concept that
type II cells contribute to alveolar defense during severe
RSV infection that in part relies upon the immune-
protective activity of SP-C.
Conclusions
RSV and other viral infections exacerbate lung disease in
young individuals with abnormalities of SP-C. A genetic
model of regulated SP-C restoration was generated and
used to determine efficacy of SP-C replacement to re-
duce RSV exacerbations in the lungs of SP-C deficient
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by induced SP-C replacement prior to infection. These
findings indicate that available commercial surfactant
extracts containing SP-C may have therapeutic value to
individuals known to have impaired SP-C production.
Type II cells isolated from the lungs of Sftpc -/- mice
and maintained in culture produced an increased in-
flammatory response to RSV indicating that the suscep-
tibility to RSV exacerbation occurs in part from an overt
response by the alveolar epithelium. Our findings infer
that SP-C abnormalities can distort the alveolar innate
immune response.
Competing interests
The authors have no competing interests to declare.
Authors’ contributions
SWG and TRK designed, supervised experiments, data analysis, prepared and
revised manuscript and prepared figures (SWG). APS prepared virus and viral
infections and revised manuscript. MDM and TLR conducted cell
transfections, type II cell isolations, in vivo infection experiments and
prepared figures. JEB prepared SP-C reagents for viral inhibition studies
prepared and revised manuscript. KP completed cytokine expression studies
of isolated type II cells and revised manuscript. All authors read and
approved the final manuscript.
Acknowledgements
The authors acknowledge the efforts of Kathryn L. Williams for genotyping
mice and for cDNA, protein analysis and John R. Ledford for completion of
the in vitro cytokine analysis. This work was funded in part by: HL050046
(SWG, TRK), AI083599 (TRK), HL085738 (JEB).
Author details
1Cincinnati Children’s Hospital Medical Center, Perinatal Institute, Division of
Neonatology, Perinatal and Pulmonary Biology, MLC7029, 3333 Burnet
Avenue, Cincinnati, OH 45229-3039, USA. 2Lovelace Respiratory Research
Institute, Albuquerque, NM, USA. 3Medical University of South Carolina,
Charleston, South Carolina, USA.
Received: 18 October 2012 Accepted: 8 February 2013
Published: 12 February 2013
References
1. Glasser SW, Baatz JE, Korfhagen TR: Surfactant protein-C in the
maintenance of lung integrity and function. J Aller Ther 2011, :S7-001. in
press.
2. Thomas AQ, Lane K, Phillips J 3rd, Prince M, Markin C, Speer M, Schwartz
DA, Gaddipati R, Marney A, Johnson J, Roberts R, Haines J, Stahlman M,
Loyd JE: Heterozygosity for a surfactant protein C gene mutation
associated with usual interstitial pneumonitis and cellular nonspecific
interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002,
165:1322–1328.
3. Gower WA, Nogee LM: Surfactant dysfunction. Paediatric Respir Rev 2011,
12:223–229.
4. Nogee LM, Dunbar AE, Wert SE, Askin F, Hamvas A, Whitsett JA: A mutation
in the surfactant protein C gene associated with familial interstitial lung
disease. N Engl J Med 2001, 344:573–579.
5. Trendano M, Griese M, Brasch F, Schumacher S, de Blic J, Maraque S,
Houdayer C, Elion J, Couderc R, Bahuau M: Mutation of SFTPC in infantile
pulmonary alveolar proteinosis with or without fibrosising lung disease.
Am J Med Genet 2004, 126A:8–26.
6. Wambach JA, Yang P, Wegner DJ, An P, Hackett BP: Surfactant protein-C
promoter variants associated with neonatal respiratory distress
syndrome reduce transcription. Ped Res 2010, 68:216–220.
7. Glasser SW, Burhans MS, Korfhagen TR, Na CL, Sly PD, Ross GF, Ikegami M,
Whitsett JA: Altered stability of pulmonary surfactant in SP-C-deficient
mice. Proc Natl Acad Sci USA 2001, 98:6366–6371.8. Glasser SW, Detmer EA, Ikegami M, Na CL, Stahlman MT, Whitsett JA:
Pneumonitis and emphysema in Sp-C gene targeted mice. J Biol Chem
2003, 278:14291–14298.
9. Bullard JE, Nogee LM: Heterozygosity for ABCA3 mutations modifies the
severity of lung disease associated with a surfactant protein C gene
(SFTPC) mutation. Ped Res 2007, 62:176–179.
10. Chibbar R, Shih F, Baga M, Torlakovic E, Ramlall K, Skomro R, Cockcroft DW,
Lemire EG: Nonspecific interstitial pneumonia and usual interstitial
pneumonia with mutation in surfactant protein C in familial pulmonary
fibrosis. Mod Pathol 2004, 17:973–980.
11. Collins PL, Melero JA: Progress in understanding and controlling
respiratory syncytial virus: still crazy after all these years. Virus Res 2011,
162:80–99.
12. Bem RA, Domachowske JB, Rosenberg HF: Animal models of human
respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol 2011,
301:L148–L156.
13. Parker D, Prince A: Innate immunity in the respiratory epithelium. Am J
Respir Cell Mol Biol 2011, 45:189–201.
14. Glasser SW, Witt TL, Senft AP, Baatz JE, Folger D, Maxfield MD, Akinbi HT,
Newton DA, Prows DR, Korfhagen TR: Surfactant protein C deficient mice
are susceptible to respiratory syncytial virus infection. Am J Physiol Lung
Cell Mol Physiol 2009, 297:L64–L72.
15. Tichelaar JW, Lu W, Whitsett JA: Conditional expression of fibroblast
growth factor-7 in the developing and mature lung. J Biol Chem 2000,
275:11858–11864.
16. Clark JC, Tichelaar JW, Wert SE, Itoh N, Perl AK, Stahlman MT, Whitsett JA:
FGT-10 disrupts lung morphogenesis and causes pulmonary ademonas
in vivo. Am J Physiol Lung Cell Mol Physiol 2001, 280:L705–L715.
17. Perl AK, Tichelaar JW, Whitsett JA: Conditional gene expression in the
respiratory epithelium of the mouse. Transgenic Res 2002, 11:21–29.
18. Furth PA, St Onge L, Böger H, Gruss P, Gossen M, Kistner A, Bujard H,
Hennighausen L: Temporal control of gene expression in transgenic mice
by a tetracycline-responsive promoter. Proc Natl Acad Sci U S A 1994,
91:9302–9306.
19. Rice WR, Conkright JJ, Na CL, Ikegami M, Shannon JM, Weaver TE:
Maintenance of the mouse type II cell phenotype in vitro. Am J Physiol
Lung Cell Mol Physiol 2002, 283:L256–L264.
20. Glasser SW, Maxfield MD, Ruetschilling TL, Akinbi HT, Baatz JE, Kitzmiller JA,
Page K, Xu Y, Bao E, Korfhagen TR: Persistence of LPS induced lung
inflammation in surfactant protein-C deficient mice. Am J Resp Cell Mol
Biol, submitted.
21. Tian B, Zhang Y, Luxon BA, Garofalo RP, Casola A, Sinha M, Brasier AR:
Identification of NF-kappaB-dependent gene networks in respiratory
syncytial virus-infected cells. J Virol 2002, 76:6800–14.
22. Whitsett JA, Wert SE, Weaver TE: Alveolar surfactant homeostasis and
pathogenesis of pulmonary disease. Ann Rev Med 2010, 61:105–119.
23. Mulugeta S, Beers MF: Surfactant protein C: its unique properties and
emerging immunomodulatory role in the lung. Microbes Infect 2006,
8:2317–2323.
24. Martinez FD: Respiratory syncytial virus bronchiolitis and the
pathogenesis of childhood asthma. Pediatr Infect Dis J 2003, 22:S76–S82.
25. Bridges JP, Xu Y, Na CL, Wong HR, Weaver TE: Adaptation and increased
susceptibility to infection associated with constitutive expression of
misfolded SP-C. J Cell Biol 2006, 172:395–407.
26. Schreiber P, Matheise JP, Dessy F, Heimann M, Letesson JJ, Coppe P, Collard
A: High mortality rate associated with bovine respiratory syncytial virus
(BRSV) infection in Belgian white blue calves previously vaccinated with
an inactivated BRSV vaccine. J Vet Med B Infect Dis Vet Public Health 2000,
47:535–550.
27. Whitsett JA, Perl AKT: Conditional control of gene expression in the
respiratory epithelium. Am J Respir Cell Mol Biol 2006, 34:519–520.
28. LeVine AM, Elliott J, Whitsett JA, Srikiatkhachorn A, Crouch E, DeSilva N,
Korfhagen TR: Surfactant protein-D enhances phagocytosis and
pulmonary clearance of respiratory syncytial virus. Am J Respir Cell Mol
Biol 2004, 31:193–199.
29. LeVine AM, Gwozdz J, Stark J, Bruno M, Whitsett J, Korfhagen T: Surfactant
protein-A enhances respiratory syncytial virus clearance in vivo. J Clin
Invest 1999, 103:1015–10121.
30. Numata M, Chu HW, Dakhama A, Voelker DR: Pulmonary surfactant
phosphatidylglycerol inhibits respiratory syncytial virus-induced
inflammation and infection. Proc Natl Acad Sci U S A 2010, 107:320–325.
Glasser et al. Respiratory Research 2013, 14:19 Page 12 of 12
http://respiratory-research.com/content/14/1/1931. Nishino M, Mizuno D, Kimoto T, Shinahara W, Fukuta A, Takei T, Sumida K,
Kitamura S, Shiota H, Kido H: Influenza vaccine with Surfacten, a modified
pulmonary surfactant, induces systemic and mucosal immune responses
without side effects in minipigs. Vaccine 2009, 27:5620–5627.
32. Mizuno D, Kimoto T, Takei T, Fukuta A, Shinahara W, Takahashi E, Yano M,
Kido H: Surfactant protein C is an essential constituent for mucosal
adjuvanticity of Surfacten, acting as an antigen delivery vehicle and
inducing both local and systemic immunity. Vaccine 2011, 29:5368–5378.
33. Glasser SW, Senft AP, Whitsett JA, Maxfield MD, Ross GF, Richardson TR,
Prows DR, Xu Y, Korfhagen TR: Macrophage dysfunction and susceptibility
to pulmonary Pseudomonas aeruginosa infection in surfactant protein C-
deficient mice. J Immunol 2008, 181:621–628.
34. Rudd BD, Burstein E, Duckett CS, Li X, Lukacs NW: Differential role for TLR3
in respiratory syncytial virus-induced chemokine expression. J Virol 2005,
79:3350–3357.
35. Groskreutz DJ, Monick MM, Powers LS, Yarovinsky TO, Look DC,
Hunninghake GW: Respiratory syncytial virus induces TLR3 protein and
protein kinase R, leading to increased double-stranded RNA
responsiveness in airway epithelial cells. J Immunol 2006, 176:1733–1740.
36. Rudd BD, Smit JJ, Flavell RA, Alexopoulou L, Schaller MA, Gruber A, Berlin
AA, Lukacs NW: Deletion of TLR3 alters the pulmonary immune
environment and mucus production during respiratory syncytial virus
infection. J Immunol 2006, 176:1937–1942.
doi:10.1186/1465-9921-14-19
Cite this article as: Glasser et al.: Genetic replacement of surfactant
protein-C reduces respiratory syncytial virus induced lung injury.
Respiratory Research 2013 14:19.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
